|
A.S. Kolbin, I.A. Vilyum, M.A. Proskurin, Yu.E. Balykina
Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care
|
№1 / 2016
|
|
V.V. Romikh, L.Yu. Borisenko, A.V. Zakharchenko
Mirabegron. Whether will be a Revolution in the Pharmacotherapy of Overactive Bladder?
|
№5 / 2015
|
|
A.I. Neymark, A.N. Voytenko, A.V. Bondarenko, N.I. Muza- levskaya, I.V. Kruglykhin
Diagnosis and Treatment of Overactive Bladder Syndrome in Pelvic Injuries
|
№5 / 2015
|
|
G.R. Kasjan
Mirabegron – a New Drug for Treatment of Overactive Bladder
|
№4 / 2015
|
|
A.A. Kotenko, L.N. Smelysheva, I.N. Kotenko
Distinctive features of vegetative and hormonal regulation in women with overactive bladder syndrome
|
№3 / 2015
|
|
G.G. Krivoborodov, E.F. Kolesanova, E.I. Tur, N.S. Efremov
Nerve growth factor in the urine of patients with idiopathic detrusor overactivity and overactive bladder without detrusor overactivity
|
№3 / 2015
|
|
Z.K. Gadzhieva
Positive effect of increasing dosage of selective antimuscarinics on the main symptoms of overactive bladder
|
№4 / 2014
|
|
Z.K. Gadzhieva, Yu.B. Kazilov, Yu.G.Alyaev, I.A. Aboyan, B.R. Kazilov
Urination disorders. Do we know all about them?
|
№1 / 2014
|
|
Vishnevsky E.L., Loran O.B., Guseva N.B., Nikitin S.S.
Features of neurohumoral regulation in children with combined dysfunction of the pelvic organs
|
№6 / 2013
|
|
Sayapova D.R., Sitdykova M.E.
Efficiency of tolterodine in the treatment of patients with overactive bladder
|
№6 / 2013
|
|
G.R. Kasyan
Flexible approach to the appointment of solifenacin: for whom and when?
|
№5 / 2013
|
|
F.N. Makhmedzhanova, I.A. Apolikhina.
Prevalence of urinary disorders and their relation to sexuality in women – point of view of gynecologist
|
№2 / 2013
|
Русский
